Found 8 matching trials
18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease
PHASE1This follow-up study continues to observe patients who have completed the p...
Location
Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik
Alzheimer's Tau Platform: Master Protocol
PHASE2The goal of the Alzheimer's Tau Platform (ATP) is to evaluate the safety an...
Location
University of California, San Francisco
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease
PHASE1This first-time-in-man study is mainly designed to assess the safety and to...
Location
Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik
The Progressive Supranuclear Palsy Clinical Trial Platform
PHASE2The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi...
Location
Stanford University
A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia
PHASE1This study is a pilot trial evaluating the safety and immunogenicity of AAD...
Location
Universitätsmedizin Göttingen, Klinik für Psychiatrie und Psychotherapie
Alzheimer's Tau Platform: Regimen A - AADvac1
PHASE2The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to eval...
Status
Enrolling By Invitation
Location
University of California, San Francisco (UCSF), Memory and Aging Center
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1
PHASE2The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi...
Status
Enrolling By Invitation
Location
University of California, San Francisco (UCSF), Memory and Aging Center
24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease
PHASE2This study evaluates the safety and efficacy of AADvac1 in the treatment of...
Location
Ordination Dr. Bancher